Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
Purpose Treatment with the radiolabelled somatostatin analogue 177 Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to 177 Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present t...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2008-04, Vol.35 (4), p.743-748 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 748 |
|---|---|
| container_issue | 4 |
| container_start_page | 743 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 35 |
| creator | van Essen, Martijn Krenning, Eric P. Kam, Boen L. de Herder, Wouter W. van Aken, Maarten O. Kwekkeboom, Dik J. |
| description | Purpose
Treatment with the radiolabelled somatostatin analogue
177
Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to
177
Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination.
Methods
Seven patients were treated with 7.4 GBq
177
Lu-octreotate and capecitabine (1650 mg/m
2
per day) for 2 weeks with an intended number of four cycles. Toxicity, and especially haematological and renal parameters, were monitored on a weekly basis for the first two cycles and 4 and 6 weeks after subsequent cycles.
Results
None of the patients had hand-foot syndrome. One patient had grade 1 stomatitis occurring after one of four cycles. Grade 3 or 4 leukopenia or neutropenia did not occur. One patient had grade 3 anaemia, but none had grade 4 anaemia. One patient had grade 2 thrombocytopenia after the fourth cycle, and one had grade 3 thrombocytopenia. Grade 4 thrombocytopenia did not occur. No significant changes in serum creatinine levels were observed. None of the patients had symptoms of cardiac ischaemia.
Conclusions
Treatment with the combination of
177
Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects. We therefore started a randomised, controlled clinical trial to compare this combination with
177
Lu-octreotate as single agent with regard to anti-tumour effects and side effects. |
| doi_str_mv | 10.1007/s00259-007-0688-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2668587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1451763471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3127-dda3c7932e9f7c3796d7abce576982711ff61ba77b91526b6ae7e7d51718e0d43</originalsourceid><addsrcrecordid>eNp1UU1r3DAQNaWlSdP-gF6K6F2tJMca6VIooV-wECjJWcjyeFchllxJTuhv6p-snF2y7SGneTPz5s2D1zRvOfvAGYOPmTHRaVohZVIpCs-aUy65psCUfv6IgZ00r3K-YYwrofTL5oQrrlTX6dPmz0-cYyokBpJ3FdCCaSLZD0hwHNGVTOJISkJbJgy1u_dlRzjAZqHR1XkstiDxgbg49T7Y4qvUA8nZGZ0vtk4fCBnvMJC5Mo5CW5tLirXHFGcb3PrHOxJwWadDdGk9LssUl5RfNy9Ge5vxzaGeNddfv1xdfKeby28_Lj5vqGu5ADoMtnWgW4F6BNeClgPY3mEHUisBnI-j5L0F6DXvhOylRUAYOg5cIRvO27Pm0153XvoJB1ftJXtr5uQnm36baL35fxP8zmzjnRFSqk5BFXh_EEjx14K5mJvqP1TPRvBz2YGArpL4nuRSzDnh-PiAM7PGa_bxmhWu8ZpV-N2_zo4XhzwrQewJua7CFtPx89OqfwGOCba9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214657275</pqid></control><display><type>article</type><title>Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>van Essen, Martijn ; Krenning, Eric P. ; Kam, Boen L. ; de Herder, Wouter W. ; van Aken, Maarten O. ; Kwekkeboom, Dik J.</creator><creatorcontrib>van Essen, Martijn ; Krenning, Eric P. ; Kam, Boen L. ; de Herder, Wouter W. ; van Aken, Maarten O. ; Kwekkeboom, Dik J.</creatorcontrib><description>Purpose
Treatment with the radiolabelled somatostatin analogue
177
Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to
177
Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination.
Methods
Seven patients were treated with 7.4 GBq
177
Lu-octreotate and capecitabine (1650 mg/m
2
per day) for 2 weeks with an intended number of four cycles. Toxicity, and especially haematological and renal parameters, were monitored on a weekly basis for the first two cycles and 4 and 6 weeks after subsequent cycles.
Results
None of the patients had hand-foot syndrome. One patient had grade 1 stomatitis occurring after one of four cycles. Grade 3 or 4 leukopenia or neutropenia did not occur. One patient had grade 3 anaemia, but none had grade 4 anaemia. One patient had grade 2 thrombocytopenia after the fourth cycle, and one had grade 3 thrombocytopenia. Grade 4 thrombocytopenia did not occur. No significant changes in serum creatinine levels were observed. None of the patients had symptoms of cardiac ischaemia.
Conclusions
Treatment with the combination of
177
Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects. We therefore started a randomised, controlled clinical trial to compare this combination with
177
Lu-octreotate as single agent with regard to anti-tumour effects and side effects.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-007-0688-7</identifier><identifier>PMID: 18188559</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject><![CDATA[Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Cancer ; Capecitabine ; Cardiology ; Clinical outcomes ; Combined Modality Therapy ; Creatinine - blood ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Endocrine system ; Fluorouracil - adverse effects ; Fluorouracil - analogs & derivatives ; Fluorouracil - therapeutic use ; Gastrointestinal diseases ; Gastrointestinal Neoplasms - drug therapy ; Gastrointestinal Neoplasms - pathology ; Gastrointestinal Neoplasms - radiotherapy ; Humans ; Imaging ; Injections, Intravenous ; Leukocyte Count ; Male ; Medicine ; Medicine & Public Health ; Neoplasm Metastasis ; Neoplasm Staging ; Neuroendocrine Tumors - drug therapy ; Neuroendocrine Tumors - pathology ; Neuroendocrine Tumors - radiotherapy ; Nuclear Medicine ; Octreotide - administration & dosage ; Octreotide - analogs & derivatives ; Octreotide - therapeutic use ; Oncology ; Organometallic Compounds - administration & dosage ; Organometallic Compounds - therapeutic use ; Original ; Original Article ; Orthopedics ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - radiotherapy ; Pharmaceuticals ; Platelet Count ; Radiation therapy ; Radioisotopes - administration & dosage ; Radioisotopes - therapeutic use ; Radiology ; Receptors, Somatostatin - drug effects ; Receptors, Somatostatin - physiology ; Side effects]]></subject><ispartof>European journal of nuclear medicine and molecular imaging, 2008-04, Vol.35 (4), p.743-748</ispartof><rights>The Author(s) 2007</rights><rights>Springer-Verlag 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3127-dda3c7932e9f7c3796d7abce576982711ff61ba77b91526b6ae7e7d51718e0d43</citedby><cites>FETCH-LOGICAL-c3127-dda3c7932e9f7c3796d7abce576982711ff61ba77b91526b6ae7e7d51718e0d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-007-0688-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-007-0688-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18188559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Essen, Martijn</creatorcontrib><creatorcontrib>Krenning, Eric P.</creatorcontrib><creatorcontrib>Kam, Boen L.</creatorcontrib><creatorcontrib>de Herder, Wouter W.</creatorcontrib><creatorcontrib>van Aken, Maarten O.</creatorcontrib><creatorcontrib>Kwekkeboom, Dik J.</creatorcontrib><title>Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose
Treatment with the radiolabelled somatostatin analogue
177
Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to
177
Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination.
Methods
Seven patients were treated with 7.4 GBq
177
Lu-octreotate and capecitabine (1650 mg/m
2
per day) for 2 weeks with an intended number of four cycles. Toxicity, and especially haematological and renal parameters, were monitored on a weekly basis for the first two cycles and 4 and 6 weeks after subsequent cycles.
Results
None of the patients had hand-foot syndrome. One patient had grade 1 stomatitis occurring after one of four cycles. Grade 3 or 4 leukopenia or neutropenia did not occur. One patient had grade 3 anaemia, but none had grade 4 anaemia. One patient had grade 2 thrombocytopenia after the fourth cycle, and one had grade 3 thrombocytopenia. Grade 4 thrombocytopenia did not occur. No significant changes in serum creatinine levels were observed. None of the patients had symptoms of cardiac ischaemia.
Conclusions
Treatment with the combination of
177
Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects. We therefore started a randomised, controlled clinical trial to compare this combination with
177
Lu-octreotate as single agent with regard to anti-tumour effects and side effects.</description><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Cancer</subject><subject>Capecitabine</subject><subject>Cardiology</subject><subject>Clinical outcomes</subject><subject>Combined Modality Therapy</subject><subject>Creatinine - blood</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Endocrine system</subject><subject>Fluorouracil - adverse effects</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastrointestinal diseases</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Gastrointestinal Neoplasms - pathology</subject><subject>Gastrointestinal Neoplasms - radiotherapy</subject><subject>Humans</subject><subject>Imaging</subject><subject>Injections, Intravenous</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Neuroendocrine Tumors - pathology</subject><subject>Neuroendocrine Tumors - radiotherapy</subject><subject>Nuclear Medicine</subject><subject>Octreotide - administration & dosage</subject><subject>Octreotide - analogs & derivatives</subject><subject>Octreotide - therapeutic use</subject><subject>Oncology</subject><subject>Organometallic Compounds - administration & dosage</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - radiotherapy</subject><subject>Pharmaceuticals</subject><subject>Platelet Count</subject><subject>Radiation therapy</subject><subject>Radioisotopes - administration & dosage</subject><subject>Radioisotopes - therapeutic use</subject><subject>Radiology</subject><subject>Receptors, Somatostatin - drug effects</subject><subject>Receptors, Somatostatin - physiology</subject><subject>Side effects</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1UU1r3DAQNaWlSdP-gF6K6F2tJMca6VIooV-wECjJWcjyeFchllxJTuhv6p-snF2y7SGneTPz5s2D1zRvOfvAGYOPmTHRaVohZVIpCs-aUy65psCUfv6IgZ00r3K-YYwrofTL5oQrrlTX6dPmz0-cYyokBpJ3FdCCaSLZD0hwHNGVTOJISkJbJgy1u_dlRzjAZqHR1XkstiDxgbg49T7Y4qvUA8nZGZ0vtk4fCBnvMJC5Mo5CW5tLirXHFGcb3PrHOxJwWadDdGk9LssUl5RfNy9Ge5vxzaGeNddfv1xdfKeby28_Lj5vqGu5ADoMtnWgW4F6BNeClgPY3mEHUisBnI-j5L0F6DXvhOylRUAYOg5cIRvO27Pm0153XvoJB1ftJXtr5uQnm36baL35fxP8zmzjnRFSqk5BFXh_EEjx14K5mJvqP1TPRvBz2YGArpL4nuRSzDnh-PiAM7PGa_bxmhWu8ZpV-N2_zo4XhzwrQewJua7CFtPx89OqfwGOCba9</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>van Essen, Martijn</creator><creator>Krenning, Eric P.</creator><creator>Kam, Boen L.</creator><creator>de Herder, Wouter W.</creator><creator>van Aken, Maarten O.</creator><creator>Kwekkeboom, Dik J.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>200804</creationdate><title>Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours</title><author>van Essen, Martijn ; Krenning, Eric P. ; Kam, Boen L. ; de Herder, Wouter W. ; van Aken, Maarten O. ; Kwekkeboom, Dik J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3127-dda3c7932e9f7c3796d7abce576982711ff61ba77b91526b6ae7e7d51718e0d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Cancer</topic><topic>Capecitabine</topic><topic>Cardiology</topic><topic>Clinical outcomes</topic><topic>Combined Modality Therapy</topic><topic>Creatinine - blood</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Endocrine system</topic><topic>Fluorouracil - adverse effects</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastrointestinal diseases</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Gastrointestinal Neoplasms - pathology</topic><topic>Gastrointestinal Neoplasms - radiotherapy</topic><topic>Humans</topic><topic>Imaging</topic><topic>Injections, Intravenous</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Neuroendocrine Tumors - pathology</topic><topic>Neuroendocrine Tumors - radiotherapy</topic><topic>Nuclear Medicine</topic><topic>Octreotide - administration & dosage</topic><topic>Octreotide - analogs & derivatives</topic><topic>Octreotide - therapeutic use</topic><topic>Oncology</topic><topic>Organometallic Compounds - administration & dosage</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - radiotherapy</topic><topic>Pharmaceuticals</topic><topic>Platelet Count</topic><topic>Radiation therapy</topic><topic>Radioisotopes - administration & dosage</topic><topic>Radioisotopes - therapeutic use</topic><topic>Radiology</topic><topic>Receptors, Somatostatin - drug effects</topic><topic>Receptors, Somatostatin - physiology</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Essen, Martijn</creatorcontrib><creatorcontrib>Krenning, Eric P.</creatorcontrib><creatorcontrib>Kam, Boen L.</creatorcontrib><creatorcontrib>de Herder, Wouter W.</creatorcontrib><creatorcontrib>van Aken, Maarten O.</creatorcontrib><creatorcontrib>Kwekkeboom, Dik J.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Essen, Martijn</au><au>Krenning, Eric P.</au><au>Kam, Boen L.</au><au>de Herder, Wouter W.</au><au>van Aken, Maarten O.</au><au>Kwekkeboom, Dik J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2008-04</date><risdate>2008</risdate><volume>35</volume><issue>4</issue><spage>743</spage><epage>748</epage><pages>743-748</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose
Treatment with the radiolabelled somatostatin analogue
177
Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to
177
Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination.
Methods
Seven patients were treated with 7.4 GBq
177
Lu-octreotate and capecitabine (1650 mg/m
2
per day) for 2 weeks with an intended number of four cycles. Toxicity, and especially haematological and renal parameters, were monitored on a weekly basis for the first two cycles and 4 and 6 weeks after subsequent cycles.
Results
None of the patients had hand-foot syndrome. One patient had grade 1 stomatitis occurring after one of four cycles. Grade 3 or 4 leukopenia or neutropenia did not occur. One patient had grade 3 anaemia, but none had grade 4 anaemia. One patient had grade 2 thrombocytopenia after the fourth cycle, and one had grade 3 thrombocytopenia. Grade 4 thrombocytopenia did not occur. No significant changes in serum creatinine levels were observed. None of the patients had symptoms of cardiac ischaemia.
Conclusions
Treatment with the combination of
177
Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects. We therefore started a randomised, controlled clinical trial to compare this combination with
177
Lu-octreotate as single agent with regard to anti-tumour effects and side effects.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>18188559</pmid><doi>10.1007/s00259-007-0688-7</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2008-04, Vol.35 (4), p.743-748 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2668587 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Cancer Capecitabine Cardiology Clinical outcomes Combined Modality Therapy Creatinine - blood Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Endocrine system Fluorouracil - adverse effects Fluorouracil - analogs & derivatives Fluorouracil - therapeutic use Gastrointestinal diseases Gastrointestinal Neoplasms - drug therapy Gastrointestinal Neoplasms - pathology Gastrointestinal Neoplasms - radiotherapy Humans Imaging Injections, Intravenous Leukocyte Count Male Medicine Medicine & Public Health Neoplasm Metastasis Neoplasm Staging Neuroendocrine Tumors - drug therapy Neuroendocrine Tumors - pathology Neuroendocrine Tumors - radiotherapy Nuclear Medicine Octreotide - administration & dosage Octreotide - analogs & derivatives Octreotide - therapeutic use Oncology Organometallic Compounds - administration & dosage Organometallic Compounds - therapeutic use Original Original Article Orthopedics Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Pancreatic Neoplasms - radiotherapy Pharmaceuticals Platelet Count Radiation therapy Radioisotopes - administration & dosage Radioisotopes - therapeutic use Radiology Receptors, Somatostatin - drug effects Receptors, Somatostatin - physiology Side effects |
| title | Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A36%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Report%20on%20short-term%20side%20effects%20of%20treatments%20with%20177Lu-octreotate%20in%20combination%20with%20capecitabine%20in%20seven%20patients%20with%20gastroenteropancreatic%20neuroendocrine%20tumours&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=van%20Essen,%20Martijn&rft.date=2008-04&rft.volume=35&rft.issue=4&rft.spage=743&rft.epage=748&rft.pages=743-748&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-007-0688-7&rft_dat=%3Cproquest_pubme%3E1451763471%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214657275&rft_id=info:pmid/18188559&rfr_iscdi=true |